<DOC>
	<DOCNO>NCT02585596</DOCNO>
	<brief_summary>This study design evaluate efficacy safety YH23537 Korea patient chronic periodontitis , order investigate recommend therapeutic dose .</brief_summary>
	<brief_title>A Phase II Clinical Trial YH23537 Patients With Chronic Periodontal Disease .</brief_title>
	<detailed_description>screen visit , least exist 18 teeth , Mild/moderate/severe periodontitis patient diagnose chronic periodontitis accord CDC / AAP ( Center Disease Control / American Academy Periodontology ) periodontitis classification ( 2012 ) .</detailed_description>
	<mesh_term>Periodontitis</mesh_term>
	<mesh_term>Chronic Periodontitis</mesh_term>
	<mesh_term>Periodontal Diseases</mesh_term>
	<mesh_term>Gingival Diseases</mesh_term>
	<criteria>Subjects must 19 year age old Have least 18 natural teeth diagnose chronic periodontitis diagnose Mild/Moderate/Severe periodontitis accord CDC / AAP periodontal classification ( 2012 ) ) Provide inform consent willingness cooperate study protocol Women childbearing potential ( WOCBP ) unwilling unable use acceptable method avoid pregnancy entire study 4 week last dose investigational product . Pregnant lactating female Systemic diseases diabetes hypertension Patients take Anticoagulants Antiplatelet Agents Continually use phenytoin , calcium channel blocker , cyclosporin , coumarin , nonsteroidal antiinflammatory drug aspirin use previous one month Patients receive periodontal treatment within last 6 month Patients malignant tumor History positive serologic evidence current infectious liver disease include HbsAg , antiHCV . Patients mental retardation dementia</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>